Table 1.
Pretreatment expression of CD2 and post-treatment changes in total cell counts for specific lymphocyte subpopulations.
| Phenotype | MFI ratio | Reduction (%) | P |
|---|---|---|---|
| Total lymphocytes | 115·9 ± 8·1 | 23·1 ± 4·2 | 0·001 |
| (112·0 ± 11·0) | (22·9 ± 5·2) | (0·0078) | |
| B cells | 0·6 ± 0·1 | 19·5 ± 6·2 | 0·004 |
| (0·6 ± 1·1) | (13·7 ± 7·6) | (0·0547) | |
| NK cells | 73·9 ± 11·1 | 10·7 ± 5·2 | 0·0813 |
| (69·3 ± 12·3) | (6·3 ± 6·7) | (0·4961) | |
| Total T cells | 149·8 ± 12·5 | 28·4 ± 5·1 | 0·0012 |
| (145·6 ± 19·2) | (27·7 ± 6·9) | (0·0117) | |
| CD4+ | 137·3 ± 12·2 | 22·4 ± 5·7 | 0·0029 |
| (135·1 ± 18·8) | (20·8 ± 6·0) | (0·0117) | |
| CD8+ | 170·1 ± 14·8 | 32·0 ± 6·1 | 0·004 |
| (161·5 ± 20·6) | (30·9 ± 9·3) | (0·0391) | |
| Naive CD4+ | 120·2 ± 12·0 | 4·8 ± 6·8 | 0·3074 |
| (118·3 ± 18·3) | (6·0 ± 14·1) | (0·8203) | |
| Memory CD4+ | 157·0 ± 14·9 | 32·7 ± 6·0 | 0·001 |
| (157·3 ± 23·6) | (33·9 ± 8·2) | (0·0117) | |
| Effector CD4+ | 191·4 ± 17·6 | 71·4 ± 4·8 | 0·0005 |
| (194·3 ± 29·6) | (74·1 ± 7·1) | (0·0039) | |
| Naive CD8+ | 154·6 ± 14·4 | 19·6 ± 7·3 | 0·0354 |
| (148·3 ± 19·4) | (16·8 ± 10·6) | (0·1289) | |
| Memory CD8+ | 182·5 ± 16·6 | 49·8 ± 7·9 | 0·0008 |
| (174·8 ± 26·6) | (56·4 ± 10·1) | (0·0078) | |
| TD CD8+ | 185·9 ± 17·2 | 36·4 ± 6·3 | 0·0024 |
| (179·9 ± 23·9) | (42·1 ± 8·9) | (0·0039) | |
| CD4+ CD45RA+ RO– | 118·4 ± 11·6 | 4·1 ± 7·4 | 0·237 |
| (117·6 ± 18·2) | (4·1 ± 5·3) | (0·4258) | |
| CD4+ CD45RA+ RO+ | 133·1 ± 12·2 | 27·6 ± 6·9 | 0·0024 |
| (135·0 ± 19·5) | (26·5 ± 7·0) | (0·0195) | |
| CD4+ CD45RA– RO+ | 143·4 ± 14·4 | 42·9 ± 6·2 | 0·0002 |
| (163·4 ± 22·6) | (44·5 ± 8·6) | (0·0039) | |
| CD8+ CD45RA+ RO– | 168·6 ± 18·8 | 20·2 ± 8·5 | 0·0681 |
| (156·9 ± 17·5) | (20·8 ± 10·3) | (0·0742) | |
| CD8+ CD45RA+ RO+ | 209·8 ± 25·7 | 59·2 ± 6·3 | 0·0002 |
| (195·6 ± 28·1) | (63·1 ± 8·5) | (0·0039) | |
| CD8+ CD45RA– RO+ | 169·5 ± 15·7 | 57·5 ± 7·4 | 0·0002 |
| (188·5 ± 23·0) | (66·3 ± 8·0) | (0·0039) | |
| CD4+ CD161+ | 209·3 ± 22·2 | 51·0 ± 5·5 | 0·0008 |
| (208·8 ± 35·8) | (49·8 ± 8·8) | (0·0078) | |
| CD8+ CD161+ | 198·6 ± 19·7 | 47·5 ± 7·6 | 0·0005 |
| (203·3 ± 33·1) | (53·3 ± 8·4) | (0·0039) | |
| CD4+ CLA+ | 180·3 ± 18·5 | 18·4 ± 10·6 | 0·0907 |
| (186·7 ± 30·1) | (22·8 ± 11·2) | (0·1641) | |
| CD8+ CLA+ | 181·9 ± 18·7 | 39·7 ± 6·2 | 0·0005 |
| (179·6 ± 31·5) | (40·6 ± 7·8) | (0·0039) | |
| CD4+ CD25high | 138·6 ± 13·0 | 11·2 ± 11·4 | 0·0727 |
| (142·7 ± 20·8) | (20·6 ± 12·0) | (0·2500) | |
| CD4+ CD25low | 153·8 ± 13·7 | 18·6 ± 13·0 | 0·0512 |
| (149·9 ± 19·6) | (13·9 ± 7·7) | (0·3008) | |
| NK T (Vα24+Vβ11+) | 157·8 ± 22·6 | 51·1 ± 6·7 | 0·0156 |
The relative expression of CD2 for each subpopulation was assessed as the median fluorescent intensity (MFI) ratio (MFI of cells staining positive for allophycocyanin-conjugated anti-CD2/MFI of isotype). The reduction in total cell count was calculated as: [total cell count at baseline − total count after 12 weeks of treatment with alefacept)/total cell count at baseline × (100)]. Positive values denote reduction in cell count, negative values denote an increase. All data are expressed as mean ± standard error of the mean (s.e.m.). Values for all included patients (n = 16, except for natural killer (NK) T cells where n = 7) in the study protocol are shown in bold type. Values for patients treated with alefacept only (n = 9) are shown in brackets. The Wilcoxon signed-rank test P-values for the reduction in cell count are specified.